https://www.selleckchem.com/pr....oducts/icec0942-hydr
07; 95% CI, 0.63-1.82), but sample sizes were not reached to allow definitive conclusions. Compared with placebo or standard care, ivabradine reduced HR (eight RCTs, 464 patients; WMD, -9.5 beats min-1; 95% CI, -13.3 to -5.8). Risk of bradycardia was not different between ivabradine and control (five RCTs, 434 patients; OR=1.2; 95% CI, 0.60-2.38). Risk of bias was overall high or unclear. CONCLUSIONS Ivabradine reduces HR compared with placebo or standard care. The effect on MACE or mortality in acute care remains unclear
Like
Comment
Share
